Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 498 / https://doi.org/10.3332/ecancer.2015.498

Policy

PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments

Concerns about rising health care costs and the often incremental nature of improvements in health outcomes continue to fuel intense debates about ‘progress’ and ‘value’ in cancer research. In times of tightening fiscal constraints, it is increasingly important for patients and their representatives to define what constitutes ’value’ to them. It is clear that diverse stakeholders have different priorities. Harmonisation of values may be neither possible nor desirable. Stakeholders lack tools to visualise or otherwise express these differences and to track progress in cancer treatments based on variable sets of values.

The Patient Access to Cancer care Excellence (PACE) Continuous Innovation Indicators are novel, scientifically rigorous progress trackers that employ a three-step process to quantify progress in cancer treatments: 1) mine the literature to determine the strength of the evidence supporting each treatment; 2) allow users to weight the analysis according to their priorities and values; and 3) calculate Evidence Scores (E-Scores), a novel measure to track progress, based on the strength of the evidence weighted by the assigned value.

We herein introduce a novel, flexible value model, show how the values from the model can be used to weight the evidence from the scientific literature to obtain E-Scores, and illustrate how assigning different values to new treatments influences the E-Scores.

The Indicators allow users to learn how differing values lead to differing assessments of progress in cancer research and to check whether current incentives for innovation are aligned with their value model. By comparing E-Scores generated by this tool, users are able to visualise the relative pace of innovation across areas of cancer research and how stepwise innovation can contribute to substantial progress against cancer over time. Learning from experience and mapping current unmet needs will help to support a broad audience of stakeholders in their efforts to accelerate and maximise progress against cancer.

Keywords: cancer, innovation, value, indicators, progress

Loading Article Metrics ... Please wait

Author interviews

Gordon McVie

European Institute of Oncology, Milan, Italy and Founding Editor of ecancer.org

Related videos

Related articles

Case Report: Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis

Abstract | Full Article | PDF Published: 22 May 2018 / https://doi.org/10.3332/ecancer.2018.837

Research: Phase I/II study on kilovoltage surface brachytherapy in conjunctival cancer: preliminary results

Abstract | Full Article | PDF | Spanish Published: 15 May 2018 / https://doi.org/10.3332/ecancer.2018.835

Review: Postoperative radiotherapy after nipple- or skin-sparing mastectomy: a review of recent institutional and pooled data

Abstract | Full Article | PDF Published: 11 May 2018 / https://doi.org/10.3332/ecancer.2018.834

Review: Aggressive breast fibromatosis following augmentation mastoplasty: a series of case reports

Abstract | Full Article | PDF | Spanish Published: 11 May 2018 / https://doi.org/10.3332/ecancer.2018.833

Short Communication: Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1

Abstract | Full Article | PDF Published: 30 Apr 2018 / https://doi.org/10.3332/ecancer.2018.831



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence